Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma.
about
Immunotherapy strategies for multiple myeloma: the present and the futureNovel immunotherapiesOptimizing dendritic cell-based immunotherapy in multiple myeloma: intranodal injections of idiotype-pulsed CD40 ligand-matured vaccines led to induction of type-1 and cytotoxic T-cell immune responses in patients.Progress on new vaccine strategies for the immunotherapy and prevention of cancer.Vaccine therapy of B cell malignancies: different strategies for a novel approach.Controversy in multiple myeloma transplants: tandem autotransplants and mini-allografts.Strategies for designing and optimizing new generation vaccines.Dendritic cell-based immunotherapy for the treatment of hematological malignancies.Cellular immunotherapy after autologous hematopoietic stem cell transplantation: experimental strategies and clinical experiences.Immunotherapy in multiple myeloma: current strategies and future prospects.Dendritic cells and malignant plasma cells: an alliance in multiple myeloma tumor progression?Dendritic cells and their potential therapeutic role in haematological malignancy.Clonal cytotoxic T cells in myeloma.Dendritic cell-based immunotherapy in multiple myeloma.Molecular monitoring of minimal residual disease in patients with multiple myeloma.Stem cell transplantation for multiple myeloma.Optimizing immunotherapy in multiple myeloma: Restoring the function of patients' monocyte-derived dendritic cells by inhibiting p38 or activating MEK/ERK MAPK and neutralizing interleukin-6 in progenitor cellsImmunotherapy using dendritic cells against multiple myeloma: how to improve?Cellular immunotherapy using dendritic cells against multiple myelomaNY-ESO-1 immunotherapy for multiple myeloma.Immunotherapy of multiple myeloma: the start of a long and tortuous journey.Advances in immunotherapy of multiple myeloma: from the discovery of tumor-associated antigens to clinical trials.Roles of idiotype-specific t cells in myeloma cell growth and survival: Th1 and CTL cells are tumoricidal while Th2 cells promote tumor growth.Immune therapies.CpG or IFN-α are more potent adjuvants than GM-CSF to promote anti-tumor immunity following idiotype vaccine in multiple myelomaDouble autologous stem cell transplantation for multiple myeloma: a Korean single center study.Drug-mediated and cellular immunotherapy in multiple myeloma.Developing dendritic cell-based therapies to condition immune responses to novel oncogenic proteins and stem cells.Targeting multiple-myeloma-induced immune dysfunction to improve immunotherapy outcomes.Novel strategies for immunotherapy in multiple myeloma: previous experience and future directions.Evolution of cellular immunotherapy: from allogeneic transplant to dendritic cell vaccination as treatment for multiple myeloma.Immunotherapeutic approaches to treat multiple myelomaImmunotherapy for multiple myeloma.Beyond consolidation: auto-SCT and immunotherapy for plasma cell myeloma.Optimizing dendritic cell vaccine for immunotherapy in multiple myeloma: tumour lysates are more potent tumour antigens than idiotype protein to promote anti-tumour immunity.Dendritic Cell Therapies for Hematologic Malignancies.Targeted idiotype-fusion DNA vaccines for human multiple myeloma: preclinical testing.Growth inhibition of myeloma cells by anti-idiotype antibodies in the absence of membrane-bound immunoglobulin.Etoposide (VP-16) plus G-CSF mobilizes different dendritic cell subsets than does G-CSF alone.Results of a Phase II clinical trial with Id-protein-loaded dendritic cell vaccine in multiple myeloma: encouraging or discouraging?
P2860
Q27021939-90764F98-1FDF-4935-879A-ECBB54D1D63EQ33822677-80727E35-C1EE-4D6D-B4C0-122828462436Q34075717-8354500B-7C8D-4F6A-B099-712322A91B7EQ34328457-FEF58BBE-D4CA-47F3-AA77-D4AC42ED5196Q34430359-00D854F9-D7F9-4762-8AD0-EE277072FF78Q34487409-6BACB779-E0ED-404B-AC9C-B8623C487381Q34572198-1DB74854-58B7-4ED4-96C9-CA16D4EC442FQ35127001-D708007B-DA54-4468-8BBD-A989CCA0ECE8Q35137164-F02B2AB3-4BD6-41CF-B998-2C76C6156ED1Q35194182-3B1BBB2C-0CE6-4EBF-ADFE-8B86CBB7F99FQ35584599-540B00B2-EC57-4132-AD12-1911456A4C51Q35614625-59F28E64-EA8C-4DAB-A130-231F470FD036Q35614630-FF79B685-6F37-48D4-AE67-42AE55A0B735Q35665926-EA8E0BA5-782A-4E07-AEB1-10911C616F80Q35668677-DC89B2C1-6244-4C2E-8B1F-C1337B5B8BEBQ35692626-FCE3E763-2469-4A80-BA22-C7A7966287FBQ35848756-6630AD0D-5CE9-4751-8155-B774B29675F5Q35852574-02AC4599-09FD-462B-9749-B3274F257749Q35865581-60B0C44D-DC62-47C9-8287-13274FA90BAEQ36637651-AF4E5DF8-38E0-4AFD-9825-FD5AD1918DBBQ36689152-A11925DF-7151-44A0-921C-95D91558E129Q36844954-2D4DBE08-A6C5-47B1-92D9-22712D282AAFQ36955402-BC7DE7AF-ED5C-42F5-9046-31F955C1416BQ36998232-4E829DB6-4CC2-4BB7-AEDF-C2F4AC2BCCAEQ37260574-7D140589-69FC-444F-AC14-509B54CCA464Q37476203-55088639-B851-4B54-8645-FF493275407DQ37773257-C547BDF5-DDC9-41AF-9B4C-9E6DF4446179Q37960189-7AB5054B-1321-4EA2-9774-370CEE2FB602Q38008379-4D731C01-0A01-4D91-8426-FFF18FFF114CQ38014834-291C55AC-6EA4-448A-8039-AF598F645505Q38059517-B9CEDB27-26BD-42B7-800C-9860753A95EFQ38171067-D44B77C6-4085-4EAF-95FA-4D08DE7C734CQ38177879-A8C31C72-22BD-406A-AE1C-1A2F472C81A7Q38370539-B27E31F8-6353-4D0D-8E21-87E25D73111AQ39265240-7FE52F2C-0EC6-4918-951F-BA819F0D6A39Q39289930-BCF26798-3F8B-45D3-AC14-D98202B2B99EQ39589735-94AA4DA2-3009-491B-AAB0-93FC02C27306Q40025045-307BCF9B-7954-469B-B75A-E1324F972E00Q44351329-472F5823-8087-41D1-89CC-8952A3A16E6AQ47562358-B5781446-38B0-406F-A924-C3FB6FE6904B
P2860
Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh-hant
name
Idiotype vaccination using den ...... antation for multiple myeloma.
@en
Idiotype vaccination using den ...... antation for multiple myeloma.
@nl
type
label
Idiotype vaccination using den ...... antation for multiple myeloma.
@en
Idiotype vaccination using den ...... antation for multiple myeloma.
@nl
prefLabel
Idiotype vaccination using den ...... antation for multiple myeloma.
@en
Idiotype vaccination using den ...... antation for multiple myeloma.
@nl
P2093
P1476
Idiotype vaccination using den ...... antation for multiple myeloma.
@en
P2093
Auffermann-Gretzinger S
Engleman EG
Rajapaksa R
Reichardt V
Stockerl-Goldstein KE
van Beckhoven A
P304
P356
10.1016/S1083-8791(00)70027-9
P577
2000-01-01T00:00:00Z